Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Expands By 51.1%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 674,952 shares, an increase of 51.1% from the March 15th total of 446,652 shares. Based on an average daily volume of 503,039 shares, the short-interest ratio is currently 1.3 days. Currently, 0.9% of the shares of the stock are sold short.

Nautilus Biotechnology Trading Up 6.2%

NAUT stock opened at $3.25 on Thursday. The company has a market cap of $411.32 million, a price-to-earnings ratio of -6.91 and a beta of 1.08. Nautilus Biotechnology has a 12 month low of $0.62 and a 12 month high of $4.31. The firm has a 50-day moving average of $2.80 and a two-hundred day moving average of $2.11.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. As a group, equities analysts forecast that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel purchased 25,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Wednesday, March 4th. The stock was purchased at an average price of $2.61 per share, for a total transaction of $65,250.00. Following the transaction, the chief executive officer directly owned 10,366,721 shares in the company, valued at approximately $27,057,141.81. This trade represents a 0.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 41.10% of the stock is currently owned by company insiders.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in NAUT. Bank of America Corp DE increased its holdings in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after buying an additional 13,363 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Nautilus Biotechnology during the 1st quarter worth approximately $194,000. Acadian Asset Management LLC increased its holdings in shares of Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after buying an additional 50,871 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Nautilus Biotechnology by 86.2% during the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after buying an additional 30,641 shares during the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth approximately $45,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Thursday, January 22nd. Guggenheim increased their price objective on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.00.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.